Roger E. Susi, Founder, CEO, President, and Chairman of Iradimed Corporation (IRMD 1.15%), reported the indirect sale of 7,500 shares of common stock over multiple transactions on May 18 and May 19, 2026, for a total value of approximately $657,000 according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (indirect) 7,500 Transaction value ~$657,000 Post-transaction shares (...
Roger E. Susi, Founder, CEO, President, and Chairman of Iradimed Corporation (IRMD 1.15%), reported the indirect sale of 7,500 shares of common stock over multiple transactions on May 18 and May 19, 2026, for a total value of approximately $657,000 according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (indirect) 7,500 Transaction value ~$657,000 Post-transaction shares (indirect) 4,397,950 Transaction value based on SEC Form 4 weighted average purchase price ($87.64). Key questions How does the size of this sale compare to Roger E. Susi's historical transaction cadence? With an average of 21.6 trades per year and typical sell tranches ranging from 5,000–10,000 shares, this 7,500-share block is consistent with the pattern established since May 2023, reflecting both historical cadence and the declining available capacity. With an average of 21.6 trades per year and typical sell tranches ranging from 5,000–10,000 shares, this 7,500-share block is consistent with the pattern established since May 2023, reflecting both historical cadence and the declining available capacity. What portion of Susi's ownership was affected by this transaction? The sale of 7,500 shares represented 0.17% of Susi's indirect holdings at the time, leaving him with 4,397,950 shares held via trust entities. The sale of 7,500 shares represented 0.17% of Susi's indirect holdings at the time, leaving him with 4,397,950 shares held via trust entities. What is the current context for Iradimed shares following this transaction? As of May 22, 2026, shares closed at $92.10, representing a one-year total return of 82.77% as of May 23, 2026, with the insider's sales occurring amid robust share price appreciation and ongoing programmatic disposition of holdings. Company overview Metric Value Revenue (TTM) $86.28 million Net income (TTM) $23.61 million Dividend yield 0.87% 1-year price change 82.77% * 1-year performance calculated using May 19th, 2026 as the reference date. Company ...